We combine oncology expertise with advanced technology and analytics to organize real world data in order to guide decisions and actions.
Together, we can bring clarity to cancer care.
We curate EHR data that can be used to drive research and standardization in order to improve patient outcomes while also reducing costs at your institution.
We make clinical sense of claims data, providing insight into performance and related outcomes across sites in order to support value-based payment models.
Our deeply curated real world data accelerates drug development informing the decisions and actions that will deliver the best drugs to patients faster and at a lower cost.
In this episode of Real World Talk, host Sandy Leonard sits down with Ulka Campbell, Head of Scientific Strategy at Aetion, and CK Wang, Chief Medical Officer at COTA. They dive into the Aetion CARE program, a cross-industry initiative aimed at understanding real-world data’s role in evaluating oncology therapeutics.
Campbell explains the importance of the CARE program, emphasizing the collaborative approach involving various stakeholders. The team is working on emulating trials, focusing on study design, data fitness, and documenting learnings. The goal is to support oncology therapeutic development, approval, and access.
Wang adds insights into the differentiation between EHR and claims data sources, highlighting the specific needs in oncology trials. The conversation concludes with a look into the future of oncology research, leaving listeners with a clear understanding of the CARE program’s significance and its potential impact on the field.
Let’s work together to transform cancer care.
